Nektar lands record $3.6B deal with Bristol-Myers Squibb for cancer immunotherapy

Bristol-Myers Squibb (NYSE:BMY) could fork over as much as $3.63 billion for the rights to Nektar Therapeutics‘ (NSDQ:NKTR) cancer immunotherapy drug, according to a deal announced today by the two companies. Nektar’s NKTR-214, which is still in development, is designed to boost the number of cancer-killing T-cells around the tumor’s micro-environment. Bristol-Myers Squibb plans to pair the investigational therapy with its own cancer drug, Opdivo, across more than 20 indications in nine tumor types. Get the full story at our sister site, Drug Delivery Business News. The post Nektar lands record $3.6B deal with Bristol-Myers Squibb for cancer immunotherapy appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Oncology Pharmaceuticals Research & Development Wall Street Beat Bristol-Myers Squibb Co. nektartherapeutics Source Type: news